MarketCap
Aptevo Therapeutics APVO
$ 1.08
-4.42%
Facebook
X
Telegram
Country |
 USA |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
316 K |
Market Cap[1] |
$ 341 K |
EBITDA (LTM) |
$ -26.1 M |
P/E (LTM) |
-0.019938 |
P/S (LTM) |
- |
EPS (LTM) |
-87.27 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
ANI Pharmaceuticals
ANIP
|
$ 71.31 | 5.19 % | $ 1.43 B | Nasdaq Global Market,SPB | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.56 | 1.3 % | $ 48.7 M | NYSE American | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.31 | -0.76 % | $ 349 M | Nasdaq Global Select Market |  Britain |
 |
Monopar Therapeutics
MNPR
|
$ 71.42 | -3.16 % | $ 529 M | Nasdaq Global Select Market | USA |
 |
BridgeBio Pharma
BBIO
|
$ 78.67 | 0.95 % | $ 15.1 B | Nasdaq Global Select Market,SPB | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 7.53 | -1.38 % | $ 1.58 B | Nasdaq Global Select Market | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.68 | -2.39 % | $ 255 M | Nasdaq Global Select Market | Britain |
 |
Coherus BioSciences
CHRS
|
$ 0.64 | -21.66 % | $ 75 M | Nasdaq Global Market | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 27.45 | 4.77 % | $ 3.49 B | Nasdaq Global Select Market,SPB | USA |
 |
Cellectis S.A.
CLLS
|
$ 1.12 | -0.45 % | $ 112 M | Nasdaq Global Market |  France |
 |
BeyondSpring
BYSI
|
$ 0.6 | -2.21 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Alkermes plc
ALKS
|
$ 46.48 | 0.67 % | $ 7.66 B | Nasdaq Global Select Market |  Irlanda |
 |
Altimmune
ALT
|
$ 1.94 | -8.51 % | $ 171 M | Nasdaq Global Market | USA |
 |
Cardiff Oncology
CRDF
|
$ 0.79 | -0.77 % | $ 52.8 M | Nasdaq Capital Market | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.5 | -5.43 % | $ 5.53 M | Nasdaq Capital Market | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 9.41 | -0.84 % | $ 258 M | Nasdaq Global Market,SPB |  Israel |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 49.04 | -0.41 % | $ 6.56 B | Nasdaq Global Select Market,SPB | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 8.18 | -0.73 % | $ 103 M | Nasdaq Global Select Market,SPB | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.3 | -1.93 % | $ 2.19 B | Nasdaq Global Market |  Canada |
 |
Cullinan Management
CGEM
|
$ 11.34 | -3.32 % | $ 683 M | Nasdaq Global Select Market | USA |
 |
BioNTech SE
BNTX
|
$ 87.2 | -0.36 % | $ 21.1 B | Nasdaq Global Select Market |  Germany |
 |
Collegium Pharmaceutical
COLL
|
$ 24.47 | -0.97 % | $ 775 M | Nasdaq Global Select Market | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 3.95 | 12.07 % | $ 52.6 M | Nasdaq Global Market | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 1.21 | -11.68 % | $ 55.3 M | Nasdaq Capital Market | Israel |
 |
AnaptysBio
ANAB
|
$ 48.4 | 0.9 % | $ 1.4 B | Nasdaq Global Select Market,SPB | USA |
 |
Assembly Biosciences
ASMB
|
$ 21.33 | -2.11 % | $ 239 M | Nasdaq Global Select Market,SPB | USA |
 |
Adagene
ADAG
|
$ 2.02 | -4.95 % | $ 119 M | Nasdaq Global Market |  China |
 |
Benitec Biopharma
BNTC
|
$ 9.31 | -5.67 % | $ 433 M | Nasdaq Capital Market | USA |
 |
Denali Therapeutics
DNLI
|
$ 19.85 | -2.36 % | $ 3.43 B | Nasdaq Global Select Market,SPB | USA |
 |
Amarin Corporation plc
AMRN
|
$ 11.75 | 0.09 % | $ 4.88 B | Nasdaq Global Market | Irlanda |
 |
ImmuCell Corporation
ICCC
|
$ 10.4 | 1.76 % | $ 93.9 M | Nasdaq Global Select Market | USA |
 |
Editas Medicine
EDIT
|
$ 2.5 | -9.09 % | $ 222 M | Nasdaq Global Select Market,SPB | USA |
 |
Agios Pharmaceuticals
AGIO
|
$ 31.77 | 1.23 % | $ 1.84 B | Nasdaq Global Select Market,SPB | USA |
 |
Cue Biopharma
CUE
|
$ 18.89 | -6.21 % | $ 1.79 B | Nasdaq Capital Market,SPB | USA |
 |
Equillium
EQ
|
$ 1.45 | -3.33 % | $ 83.1 M | Nasdaq Global Market | USA |
 |
Black Diamond Therapeutics
BDTX
|
$ 1.6 | -14.05 % | $ 91 M | Nasdaq Global Select Market,SPB | USA |
 |
Abeona Therapeutics
ABEO
|
$ 2.46 | -3.35 % | $ 130 M | Nasdaq Capital Market | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 18.13 | 9.85 % | $ 3.05 B | Nasdaq Global Select Market,SPB | USA |
 |
Atossa Therapeutics
ATOS
|
$ 2.21 | 3.76 % | $ 19 M | Nasdaq Capital Market | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
- | -7.31 % | $ 49 M | Nasdaq Capital Market | USA |
 |
Five Prime Therapeutics, Inc.
FPRX
|
- | - | $ 1.77 B | Nasdaq Global Select Market | USA |
 |
ADC Therapeutics SA
ADCT
|
$ 1.51 | -9.88 % | $ 192 M | NYSE |  Schweiz |
 |
Harmony Biosciences Holdings
HRMY
|
$ 33.57 | -0.62 % | $ 1.93 B | Nasdaq Global Select Market | USA |
 |
Ardelyx
ARDX
|
$ 3.0 | 2.39 % | $ 723 M | Nasdaq Global Market | USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.54 | 1.8 % | $ 139 M | Nasdaq Global Market | USA |
 |
Alector
ALEC
|
$ 2.54 | 3.05 % | $ 262 M | Nasdaq Global Select Market,SPB | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.11 | -13.62 % | $ 59.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Amneal Pharmaceuticals
AMRX
|
$ 21.39 | 0.52 % | $ 6.7 B | NYSE | USA |
|
Phathom Pharmaceuticals
PHAT
|
$ 5.45 | 2.16 % | $ 397 M | Nasdaq Global Select Market,SPB | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 3.8 | 2.15 % | $ 728 M | Nasdaq Global Select Market | Canada |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.